multiple sclerosis

by Medical University of Vienna edited by Lisa Lock, reviewed by Andrew Zinin EBNA-1381-452-specific IgG antibody titers are a biomarker for the future diagnosis of MS. Credit: Nature Communications (2025). DOI: 10.1038/s41467-025-61751-9 A research team at the Medical University of Vienna has developed a blood test that allows the identification of individuals at risk for developing multiple sclerosis (MS) with […]

by Yale School of Medicine edited by Lisa Lock, reviewed by Robert Egan   Microglia-like CSF macrophages increase in frequency in patients with MS following B cell depletion therapy. Credit: Journal of Clinical Investigation (2025). DOI: 10.1172/JCI182790 When ocrelizumab became the first FDA-approved treatment for early forms of multiple sclerosis (MS) in 2017, it offered patients immense hope. The long-awaited

First-of-its kind study reveals signs of premature biological aging in teenagers with MS pointing to new treatment possibilities beyond immunosuppression Peer-Reviewed Publication University of California – San Diego FacebookXLinkedInWeChatBlueskyMessageWhatsAppEmail Researchers from University of California San Diego School of Medicine have discovered that children living with multiple sclerosis (MS) show signs of accelerated biological aging, even